Praxbind

Praxbind

idarucizumab

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH

Marketer:

Boehringer Ingelheim
Concise Prescribing Info
Contents
Idarucizumab
Indications/Uses
Specific reversal agent for dabigatran & in patients treated w/ dabigatran when rapid reversal of anticoagulant effects is required for emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding.
Dosage/Direction for Use
5 g (2 x 2.5 g/50 mL) IV as 2 consecutive infusions over 5-10 min each or as bolus inj. Bleeding recurrence/potential life-threatening re-bleeding/2nd emergency surgery/urgent procedure w/ prolonged clotting time 2nd 5-g dose may be considered. Restarting antithrombotic therapy Reinitiated after 24 hr & other antithrombotic therapy eg, LMWH may be started at any time if clinically stable & adequate hemostasis has been achieved.
Special Precautions
Discontinue use if anaphylactic reaction or other serious allergic reaction occurs. Thrombotic risk of underlying disease. Patients on controlled Na diet. Fructose intolerance. Consider transient proteinuria for urine testing. Pregnancy & lactation. Childn <18 yr.
ATC Classification
V03AB37 - idarucizumab ; Belongs to the class of antidotes. Used to reverse anticoagulant effects of dabigatran.
Presentation/Packing
Form
Praxbind soln for inj 50 mg/mL
Packing/Price
50 mL x 2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in